Introduction {#H1-1-ZOI200316}
============

The misuse, overdose, and abuse of prescription opioids constitute sources of substantial morbidity and mortality in the US and globally.^[@zoi200316r1],[@zoi200316r2],[@zoi200316r3],[@zoi200316r4],[@zoi200316r5]^ Approximately 130 individuals in the US die each day of opioid overdose, with one of the largest proportion of preventable deaths in the US being attributable to opioid-related deaths.^[@zoi200316r3]^ In addition to the substantial mortality burden, prescription opioid misuse, abuse, dependence, and overdose were reported to cost the US health care system an estimated \$78.5 billion in 2013.^[@zoi200316r6]^ Increases in prescription opioid use and incidence of opioid-related deaths have also been reported globally, including in European countries and Canada.^[@zoi200316r4],[@zoi200316r5],[@zoi200316r7],[@zoi200316r8],[@zoi200316r9]^

Many of the efforts to curb the opioid crisis in the US have focused on regulatory changes regarding opioid use for chronic, noncancer pain, with the guidance for postoperative opioid analgesia use being less clear.^[@zoi200316r10],[@zoi200316r11],[@zoi200316r12]^ The medical literature^[@zoi200316r12],[@zoi200316r13]^ purports that inappropriate opioid prescribing for peri- and postoperative analgesia in the form of inadequate or excessive dispensing may contribute to the ongoing epidemic. Of note, opioids remain the standard of care for treatment of acute and routine postoperative pain,^[@zoi200316r14],[@zoi200316r15]^ and surgical procedures remain the primary reason for exposure to these medications.^[@zoi200316r12],[@zoi200316r16]^ There is also substantial variation in opioid prescribing among clinicians, particularly in the quantities and dosages of opioids after common general surgical procedures.^[@zoi200316r17],[@zoi200316r18]^ This variation is further complicated with the potential for misuse and diversion, with 67% to 92% of all opioids prescribed for postoperative pain remaining unused.^[@zoi200316r19]^

The association between opioid prescribing after surgery and the opioid crisis is complex. Inadequate postoperative pain management, including using opioids, has been reported to be associated with increased risk for chronic pain, thus warranting the need for long-term opioid use.^[@zoi200316r20],[@zoi200316r21],[@zoi200316r22],[@zoi200316r23],[@zoi200316r24],[@zoi200316r25]^ Conversely, the receipt of prescription opioids after surgery is suggested to be associated with increased risk for chronic opioid use. In a retrospective analysis of population-based claims data from Canada,^[@zoi200316r26]^ individuals prescribed opioids within 7 days of a low-risk surgical procedure were 44% more likely to become prolonged opioid users within 1 year after surgery compared with individuals who did not receive these medications. Lastly, undergoing a surgical procedure has been hypothesized as an independent risk factor for prolonged opioid use after surgery.^[@zoi200316r11],[@zoi200316r12],[@zoi200316r27],[@zoi200316r28],[@zoi200316r29]^

Although several studies have sought to quantify the rate of and characterize risk factors for prolonged opioid use after surgery, the extent and strength of association have been inconsistent. Despite using similar definitions of prolonged opioid use and eligibility criteria, studies^[@zoi200316r30],[@zoi200316r31],[@zoi200316r32]^ enrolling opioid-naive patients undergoing major surgical procedures in the US reported incidence rates ranging from 0.5% to 13.0%. Incidence rates as high as 44% for 1 year after surgery have also been reported.^[@zoi200316r33],[@zoi200316r34]^ To address these conflicting results and to account for potential bias related to differences in study-level factors and low sample sizes, we performed a meta-analysis of published literature to systematically characterize and aggregate the magnitude and patient-level risk factors associated with increased risk of prolonged opioid use after surgery.

Methods {#H1-2-ZOI200316}
=======

This systematic review and meta-analysis was conducted according to the Meta-analysis of Observational Studies in Epidemiology ([MOOSE](https://www.equator-network.org/reporting-guidelines/meta-analysis-of-observational-studies-in-epidemiology-a-proposal-for-reporting-meta-analysis-of-observational-studies-in-epidemiology-moose-group/)) and Preferred Reporting Items for Systematic Reviews and Meta-analyses ([PRISMA](https://www.equator-network.org/reporting-guidelines/prisma/)) reporting guidelines.^[@zoi200316r35],[@zoi200316r36]^ The study protocol is available in the PROSPERO database ([CRD42019129239](https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=129239)).

Literature Search {#H2-1-ZOI200316}
-----------------

Relevant studies were identified through an initial literature search of MEDLINE, Embase, and Google Scholar from inception of these databases to August 30, 2017, with an updated search performed on June 30, 2019. Eligible studies were identified from electronic databases using search terms and keywords such as *opioid analgesics, general surgery, surgical procedures, persistent opioid use,* and *postoperative pain*. The full search strategy is available in the eAppendix in the [Supplement](#note-ZOI200316-1-s){ref-type="supplementary-material"}. We also searched bibliographies of relevant articles to identify additional eligible publications.

Study Selection {#H2-2-ZOI200316}
---------------

Two of us (J.G. and A.M.) independently assessed all titles and abstracts of studies to determine studies eligible for full-text review. Eligible studies were restricted to published observational studies evaluating opioid use after surgery. Studies were included if they (1) were published in the English language; (2) enrolled participants 18 years or older; (3) included a minimum of 50 patients; (4) involved a noninjectable opioid prescription fill at least 3 months after the index surgical procedure; and (5) reported the rate and adjusted outcome estimates for patient-level risk factors associated with prolonged opioid use after surgery. Given differences with opioid use in cancer vs noncancer pain management, we excluded studies evaluating cancer pain. In addition, eligible studies needed to have accounted for opioids dispensed in the perioperative period or to have incorporated a lag period for at least 1 month after the index surgical procedure. This criterion was included to account for opioids prescribed as part of routine management of postoperative pain before assessing prolonged opioid use after surgery.

Currently, there is not an accepted definition of prolonged opioid use in the medical literature. Therefore, all studies that met the inclusion criteria were considered regardless of variations in the operational definition of prolonged opioid use within and among studies. However, because opioids are often prescribed preemptively to manage peri- or postoperative pain during the few days or months, in some instances, after surgery, we set a 3-month threshold after the index surgical procedure before assessing prolonged opioid use. As such, prolonged opioid use in this study refers to any opioid use pattern reported by the included studies occurring at least 3 months after surgery. An exception is use of the term *chronic opioid use*. Based on previous literature,^[@zoi200316r2],[@zoi200316r11],[@zoi200316r37],[@zoi200316r38],[@zoi200316r39],[@zoi200316r40]^ we defined *chronic opioid use* as the receipt of at least 10 opioid prescription fills, at least 90 consecutive days' supply of opioids, or 120 cumulative days in the first year after surgery, excluding the initial 90 postoperative days. Because we expected substantial between-study variation in prolonged opioid use definitions, in sensitivity analyses, we repeated our primary analysis to assess the pooled rate of prolonged opioid use by aggregating evidence across studies involving comparable definitions for opioid use after surgery (eTable 1 in the [Supplement](#note-ZOI200316-1-s){ref-type="supplementary-material"}).

Data Extraction {#H2-3-ZOI200316}
---------------

Data extraction was performed by the same 2 reviewers (J.G. and A.M.) from the literature search using structured forms. A third reviewer (O.D.L.) assessed the data extraction forms for completeness and accuracy. Extracted information from eligible studies included the study design, sample size, length of follow-up, types of surgical procedure, proportions of opioid-naive and opioid-experienced individuals at baseline, and the definitions of prolonged opioid use after surgery. In addition, rates and adjusted estimates associated with the longest follow-up time were extracted. We did not contact authors for information missing from published texts.

Quality Assessment {#H2-4-ZOI200316}
------------------

The quality of included studies was assessed by 2 independent reviewers (O.D.L. and J.G.) using the Newcastle-Ottawa Scale,^[@zoi200316r41]^ and disagreements were resolved by discussion. Studies with a Newcastle-Ottawa Scale score greater than 7 were considered to be high in quality.

Statistical Analysis {#H2-5-ZOI200316}
--------------------

The primary outcomes of interest were the pooled rate and magnitude for individual risk factors of prolonged opioid use after surgery. No restrictions were made in the type of effect estimates extracted; therefore, studies reporting odds ratios (ORs), risk ratios, or hazard ratios were eligible for inclusion. Based on the overall low prevalence of the risk factors in the individual studies (ie, \<10%), we regarded risk ratios and ORs as equivalent risk measures. However, we pooled studies reporting hazard ratios in a separate analysis. We calculated the pooled rate of prolonged opioid use after surgery weighted by the sample size of each eligible study. When 2 or more studies reported adjusted estimates for the same risk factor, a pooled OR and the corresponding 95% CI were estimated using the inverse variance method with a random-effects model.^[@zoi200316r42]^ Based on an a priori assumption of substantial between-study variation, we prespecified to use the random-effects model for all meta-analyses. Between-study heterogeneity was tested using the Cochran Q statistic^[@zoi200316r43]^ and quantified by the *I*^2^ value.^[@zoi200316r44]^ We considered heterogeneity to be significant at *P* \< .10 and *I*^2^\>50% to indicate substantial between-study variation that was beyond chance.^[@zoi200316r45]^ Heterogeneity was further assessed in sensitivity analyses. Small-study effect, commonly referred to as publication bias, was examined using a funnel plot and the Egger regression test. Except for heterogeneity, statistical significance was set at *P* \< .05; all tests were 2-sided. Statistical analyses were conducted using Comprehensive Meta-Analysis Software, version 3.0 (Biostat).

We performed additional analyses to evaluate the potential sources of heterogeneity and robustness of the primary findings. First, we restricted our analyses to studies enrolling only opioid-naive patients before surgery. We accepted definitions of opioid naive from each eligible study. The definitions of opioid naivety in studies enrolling only opioid-naive participants are presented in eTable 2 in the [Supplement](#note-ZOI200316-1-s){ref-type="supplementary-material"}. Second, we examined whether the rate of prolonged opioid use after surgery differed by source population or insurance plan, follow-up period (≤6 months vs \>6 months), type of surgery (major vs minor surgery and orthopedic vs nonorthopedic surgery), and studies conducted in the US vs non-US countries to assess whether our main finding was moderated by potential differences in prescribing patterns across countries. Classification of major or minor surgery was based on previously published reports^[@zoi200316r11],[@zoi200316r12],[@zoi200316r46]^ and expert opinion (E.B.) (eTable 3 in the [Supplement](#note-ZOI200316-1-s){ref-type="supplementary-material"}). We then aggregated evidence across studies involving comparable definitions for chronic or prolonged opioid use after surgery. Lastly, for each risk factor reported by at least 3 studies, we recalculated the pooled effect by omitting 1 study at a time. This leave-one-out analysis was performed to determine the influence of an individual study on the pooled effects.

Results {#H1-3-ZOI200316}
=======

Study Selection {#H2-6-ZOI200316}
---------------

The search of electronic databases yielded 7534 citations. After removal of duplicates and full-text reviews, a total of 33 studies involving 1 922 743 individuals, with 1 854 006 (96.4%) from the US.^[@zoi200316r11],[@zoi200316r12],[@zoi200316r16],[@zoi200316r27],[@zoi200316r29],[@zoi200316r30],[@zoi200316r31],[@zoi200316r32],[@zoi200316r33],[@zoi200316r46],[@zoi200316r47],[@zoi200316r48],[@zoi200316r49],[@zoi200316r50],[@zoi200316r51],[@zoi200316r52],[@zoi200316r53],[@zoi200316r54],[@zoi200316r55],[@zoi200316r56],[@zoi200316r57],[@zoi200316r58],[@zoi200316r59],[@zoi200316r60],[@zoi200316r61],[@zoi200316r62],[@zoi200316r63],[@zoi200316r64],[@zoi200316r65],[@zoi200316r66],[@zoi200316r67],[@zoi200316r68],[@zoi200316r69]^ The PRISMA diagram is shown in [Figure 1](#zoi200316f1){ref-type="fig"}.

![PRISMA Flow Diagram of Included Studies](jamanetwopen-3-e207367-g001){#zoi200316f1}

Study Characteristics {#H2-7-ZOI200316}
---------------------

Characteristics of the eligible studies are presented in [Table 1](#zoi200316t1){ref-type="table"}. Sample sizes of included studies ranged from 109 to 675 527 participants. The included studies were conducted in Australia, Canada, Denmark, France, the US, and the UK, with 26 (78.8%) from the US. Of the 1 247 216 individuals enrolled in 32 studies with sex information,^11,12,16,27,29-33,46,48-69^ 1 031 399 (82.7%) were females. Information on age was available in 22 studies^11,12,27,29,30,33,48,50,53,54,58-60,62-69^; the mean (SD) age of participants was 59.3 (12.8) years. The minimum age of participants was 39.0 years and the maximum age was 80.0 years. Of the 33 studies, 14 (42.4%) involved data from commercial insurance plans, 12 (36.4%) used hospital institution data, 5 (15.2%) involved military or veterans' insurance plans, and the remaining 2 (6.1%) were based on data from national, publicly funded health care systems. Eight studies (24.2%) enrolled only opioid-naive participants,^[@zoi200316r11],[@zoi200316r12],[@zoi200316r16],[@zoi200316r30],[@zoi200316r31],[@zoi200316r32],[@zoi200316r46],[@zoi200316r50]^ 18 (54.5%) enrolled both opioid-naive and opioid-experienced participants,^[@zoi200316r27],[@zoi200316r29],[@zoi200316r33],[@zoi200316r48],[@zoi200316r49],[@zoi200316r51],[@zoi200316r52],[@zoi200316r55],[@zoi200316r56],[@zoi200316r57],[@zoi200316r58],[@zoi200316r59],[@zoi200316r60],[@zoi200316r61],[@zoi200316r66],[@zoi200316r70]^ and the remaining 7 studies lacked sufficient information to categorize participants.^[@zoi200316r47],[@zoi200316r53],[@zoi200316r54],[@zoi200316r62],[@zoi200316r63],[@zoi200316r64],[@zoi200316r65]^ The definitions of *long-term*, *persistent*, and *prolonged opioid use* and *opioid naivety* varied across studies ([Table 1](#zoi200316t1){ref-type="table"}, and eTables 1-2 in the [Supplement](#note-ZOI200316-1-s){ref-type="supplementary-material"}). Subgroup analysis based on quality was not performed because the individual summed score from the Newcastle-Ottawa-Scale varied between 7 and 9, suggesting that all included studies were high quality.

###### Characteristics of Included Studies

  Source                                      Country     Type of surgery                                                                                                                                                                                                                                                                                                             Data source or study setting                                                             Participants, No.   Median age at baseline, y   Enrollment period                        No. (%)         Type of prolonged opioid use and definition   Follow-up time   NOWS score                                                                                                                                                                                                   
  ------------------------------------------- ----------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------- ------------------- --------------------------- ---------------------------------------- --------------- --------------------------------------------- ---------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------- ---
  Bateman et al,^[@zoi200316r16]^ 2016        US          Cesarean delivery                                                                                                                                                                                                                                                                                                           Commercial insurance beneficiaries                                                       80 127              NR                          January 1, 2003, to December 31, 2011    80 127 (100)    285 (0.4)                                     285 (0.4)        Persistent use; using a trajectory model with 5 patient groups based on probability of an opioid fill during each of 12 consecutive 30-d follow-up; opioid fill in ≥4, 6, or 8 mo of follow-up   1 y         9
  Raebal et al,^[@zoi200316r27]^ 2014         US          Bariatric surgery                                                                                                                                                                                                                                                                                                           Commercial insurance beneficiaries                                                       10 643              47                          January 1, 2005, to December 31, 2009    6483 (60.9)     421 (4.0)                                     84 (1.3)         Chronic opioid use defined as ≥10 fills dispensing ≥90 consecutive days or ≥120-d total supply                                                                                                   1 y         9
  Clarke et al,^[@zoi200316r46]^ 2014         Canada      Major elective surgeries                                                                                                                                                                                                                                                                                                    National health care system databases                                                    39 140              NR                          April 1, 2003, to March 31, 2010         39 140 (100)    1229 (3.1)                                    1229 (3.1)       Prolonged opioid use defined as the filling of opioid fills within the first 90 d after surgery and ≥1 opioid fill for 91-180 d after surgery                                                    6 mo        9
  Shah et al,^[@zoi200316r47]^ 2017           US          Urologic surgery                                                                                                                                                                                                                                                                                                            Hospital institution data                                                                675 527             62                          2007-2011                                NR              608 (0.1)                                     NR               Opioid dependence; outcome was assessed on the presence of *ICD-9* diagnosis codes                                                                                                               1 y         9
  Sun et al,^[@zoi200316r11]^ 2016            US          Total knee arthroplasty, total hip arthroplasty, laparoscopic cholecystectomy, open cholecystectomy, laparoscopic appendectomy, open appendectomy, cesarean delivery, functional endoscopic sinus surgery, cataract surgery, transurethral prostate resection, and simple mastectomy                                        Commercial insurance beneficiaries                                                       641 941             44                          Jan 1, 2001, to Dec 31, 2013             641 941 (100)   2039 (0.3)                                    2039 (0.3)       Chronic opioid use defined as ≥10 opioid fills or ≥120-d supply of an opioid in the first 365 d after surgery, excluding the first 90 d after surgery                                            1 y         9
  Connolly et al,^[@zoi200316r48]^ 2017       US          Lumbar spinal fusion surgery                                                                                                                                                                                                                                                                                                Commercial insurance beneficiaries                                                       8377                49.6                        January 1, 2009, to December 31, 2012    1332 (15.9)     2458 (29.3)                                   29 (2.2)         Long-term opioid use defined as opioid fill at least 365 d in 24 mo after surgery                                                                                                                2 y         9
  Bedard et al,^[@zoi200316r49]^ 2017         US          Total knee arthroplasty                                                                                                                                                                                                                                                                                                     Commercial insurance beneficiaries                                                       73 959              NR                          January 1, 2007, to December 31, 2014    29 801 (40.3)   8780 (11.8)                                   969 (3.2)        Prolonged opioid use defined as opioid fill each mo for up to 1 y after surgery                                                                                                                  1 y         9
  Johnson et al,^[@zoi200316r31]^ 2016        US          Hand surgery                                                                                                                                                                                                                                                                                                                Commercial insurance beneficiaries                                                       59 725              NR                          January 1, 2010, to December 31, 2012    59 725 (100)    7764 (13.0)                                   7764 (13.0)      Prolonged opioid use defined as ≥1 opioid fill between 30 d before and 2 wk after surgery and ≥1 opioid prescription 90-180 d after surgery                                                      6 mo        9
  Schoenfeld et al,^[@zoi200316r50]^ 2017     US          Spine surgery: discectomy, decompression, lumbar posterolateral arthrodesis, or lumbar interbody arthrodesis                                                                                                                                                                                                                Military insurance beneficiaries, TRICARE                                                9991                46.4                        January 1, 2006, to December 31, 2014    9991 (100)      2 (0.02)                                      2 (0.02)         Sustained opioid use defined as continued opioid use up to 6 mo after surgery                                                                                                                    1 y         9
  Westermann et al,^[@zoi200316r51]^ 2017     US          Rotator cuff repair                                                                                                                                                                                                                                                                                                         Commercial insurance beneficiaries                                                       35 155              NR                          January 1, 2007, to December 31, 2014    19 925 (56.7)   6749 (19.2)                                   1594 (8.0)       Prolonged opioid use defined as opioid fill each mo up to 1 y after surgery                                                                                                                      3 mo        9
  Rosenbloom et al,^[@zoi200316r53]^ 2017     Canada      Traumatic musculoskeletal injury and corrective surgery                                                                                                                                                                                                                                                                     Hospital institution data                                                                122                 44.8                        May 2012 to July 2013                    NR              43 (35.2)                                     NR               Persistent opioid use defined as ≥1 opioid fill 4 mo after surgery                                                                                                                               4 mo        8
  Brummett et al,^[@zoi200316r12]^ 2017       US          Surgical procedure: major, ventral incisional hernia repair, colectomy, reflux surgery, bariatric surgery, and hysterectomy; minor, varicose vein removal, laparoscopic cholecystectomy, laparoscopic appendectomy, hemorrhoidectomy, thyroidectomy, transurethral prostate surgery, parathyroidectomy, and carpal tunnel   Commercial insurance beneficiaries                                                       36 177              44.6                        January 1, 2012, to June 30, 2015        36 177 (100)    2176 (6.0)                                    2176 (6.0)       Persistent opioid use defined as opioid fill 90-180 d after surgery                                                                                                                              6 mo        9
  Fuzier et al,^[@zoi200316r54]^ 2018         France      Carpal tunnel surgery                                                                                                                                                                                                                                                                                                       National health care system                                                              3665                58                          January 1 to June 30, 2010               NR              183 (5.0)                                     NR               Prolonged opioid use defined as opioid fill each month from 2 mo before surgery to \>2 to 12 mo after surgery                                                                                    1 y         9
  Carroll et al,^[@zoi200316r55]^ 2012        US          Mastectomy, lumpectomy, thoracotomy, and total hip or knee replacement                                                                                                                                                                                                                                                      Hospital institution data                                                                109                 NR                          January 2007 to April 2009               21 (19.3)       6 (5.5)                                       NR               Opioid use 150 d after surgery                                                                                                                                                                   150 d       8
  Pugely et al,^[@zoi200316r56]^ 2018         US          Cervical spine surgery                                                                                                                                                                                                                                                                                                      Commercial insurance beneficiaries                                                       17 391              NR                          2007-2015                                8278 (47.6)     4128 (45.3)                                   522 (6.3)        Prolonged opioid use defined as opioid prescription fill per month for 1 y after surgery                                                                                                         1 y         9
  Politzer et al,^[@zoi200316r57]^ 2018       US          Total knee arthroplasty                                                                                                                                                                                                                                                                                                     Commercial insurance beneficiaries                                                       66 950              NR                          2007-2013                                30 282 (45.2)   12 760 (34.6)                                 1514 (5.0)       Chronic opioid use defined as opioid fill for 6 contiguous months after surgery                                                                                                                  2 y         9
  Swenson et al,^[@zoi200316r32]^ 2018        US          Hysterectomy                                                                                                                                                                                                                                                                                                                Commercial insurance beneficiaries                                                       24 331              NR                          January 1, 2011, to December 31, 2014    24 331 (100)    122 (0.5)                                     122 (0.5)        Persistent opioid use defined as ≥2 opioid fills within 6 mo after surgery with ≥1 fill every mo and either total oral morphine equivalent of at least 1500 or at least 39 d of opioid supply    6 mo        8
  Namba et al,^[@zoi200316r33]^ 2018          US          Total knee arthroplasty                                                                                                                                                                                                                                                                                                     Hospital institution data                                                                23 726              68                          January 1, 2008, to December 31, 2011    14 236 (40.0)   7218 (30.4)                                   NR               Prolonged opioid use defined as number of opioid fills every 90-d period 1 y after surgery                                                                                                       1 y         9
  Bennett et al,^[@zoi200316r30]^ 2019        US          Body contouring surgical procedures after bariatric surgery                                                                                                                                                                                                                                                                 Commercial insurance beneficiaries                                                       11 257              41.0                        January 1, 2002, to September 30, 2014   11 257 (100)    690 (6.1)                                     690 (6.1)        Persistent opioid use defined as continued opioid fills 90-180 d after surgery among patients who had opioid fills perioperatively                                                               6 mo        8
  Westermann et al,^[@zoi200316r52]^ 2019     US          Hip arthroscopy                                                                                                                                                                                                                                                                                                             Commercial insurance beneficiaries                                                       1208                NR                          January 1, 2007, to June 30, 2016        698 (57.8)      183 (15.1)                                    37 (5.3)         Prolonged opioid use defined as opioid fills each mo up to 1 y after surgery                                                                                                                     1 y         9
  Goesling et al,^[@zoi200316r58]^ 2016       US          Total knee and total hip arthroplasty                                                                                                                                                                                                                                                                                       Hospital institution data                                                                574                 63.3                        March 2010 to May 2013                   407 (70.9)      70 (12.2)                                     20 (4.9)         Persistent opioid use defined as opioid fills at 6 mo after surgery                                                                                                                              6 mo        7
  Lindestrand et al,^[@zoi200316r59]^ 2015    Denmark     Hip fracture surgery                                                                                                                                                                                                                                                                                                        Hospital institution data                                                                413                 79.5                        May 30, 2010, to March 31, 2011          314 (76.0)      124 (30.2)                                    9 (2.9)          Persistent opioid use defined as opioid fills 90 and 180 d after surgery                                                                                                                         6 mo        9
  Mulligan et al,^[@zoi200316r60]^ 2016       US          Ankle and foot reconstruction                                                                                                                                                                                                                                                                                               Hospital institution data                                                                132                 55                          NR                                       89 (67.4)       52 (39.4)                                     14 (15.7)        Defined as continued opioid use for 3 mo after surgery                                                                                                                                           1 y         8
  Rao et al,^[@zoi200316r61]^ 2018            US          Shoulder arthroplasty                                                                                                                                                                                                                                                                                                       Hospital institution data                                                                4243                NR                          January 1, 2008, to December 31, 2014    1061 (25.0)     1598 (40.0)                                   NR               Persistent opioid use defined as opioid use after surgery within 1 y of surgery, evaluated quarterly                                                                                             1 y         9
  Singh and Lewallen,^[@zoi200316r62]^ 2010   US          Primary total hip arthroplasty                                                                                                                                                                                                                                                                                              Hospital institution data                                                                3005                64.9                        1993-2005                                NR              85 (2.8)                                      NR               Opioid use after surgery assessed by validated questionnaire given 2 and 5 y after index surgery                                                                                                 2 and 5 y   7
  Singh and Lewallen,^[@zoi200316r63]^ 2012   US          Primary total knee arthroplasty                                                                                                                                                                                                                                                                                             Hospital institution data                                                                4234                68                          1993-2005                                NR              61 (1.4)                                      NR               Opioid use after surgery assessed by validated questionnaire given 2 and 5 y after index surgery                                                                                                 2 and 5 y   7
  Singh and Lewallen,^[@zoi200316r64]^ 2014   US          Revision total knee arthroplasty                                                                                                                                                                                                                                                                                            Hospital institution data                                                                881                 69                          1993-2005                                NR              52 (5.9)                                                       Opioid use after surgery assessed by validated questionnaire given 2 and 5 y after index surgery                                                                                                 2 and 5 y   7
  Valdes et al,^[@zoi200316r65]^ 2015         UK          Total joint replacement                                                                                                                                                                                                                                                                                                     Hospital institution data                                                                852                 73.7                        2008-2014                                NR              215 (25.1)                                    NR               Opioid use after surgery assessed by questionnaire given 1.27 y after index surgery                                                                                                              4 y         7
  Rozet et al,^[@zoi200316r66]^ 2014          US          Knee arthroscopy                                                                                                                                                                                                                                                                                                            Military insurance beneficiaries, Veterans Affairs                                       145                 39                          2007-2010                                82 (56.6)       43 (30.0)                                     NR               Prolonged opioid use defined as opioid fills uninterruptedly for \>3 mo after surgery                                                                                                            3.5 mo      8
  Kim et al,^[@zoi200316r29]^ 2017            US          Hip or knee arthroplasty                                                                                                                                                                                                                                                                                                    Commercial insurance beneficiaries                                                       57 545              61.5                        January 1, 2004, to December 31, 2013    7425 (12.9)     4373 (7.6)                                    48 (0.6)         Persistent opioid use defined as ≥1 opioid fill each mo during the 1 y after surgery based on group-based trajectory models                                                                      1 y         9
  Hansen et al,^[@zoi200316r67]^ 2017         Australia   Total knee arthroplasty                                                                                                                                                                                                                                                                                                     Military insurance beneficiaries, Australian Government Department of Veterans Affairs   15 020              79                          January 1, 2001, to December 31, 2012    9223 (61.4)     787 (5.2)                                     64 (0.7)         Chronic opioid use defined as \>90 d of continuous opioid use or \>120 d of cumulative use                                                                                                       1 y         9
  Inacio et al,^[@zoi200316r68]^ 2016         Australia   Total hip arthroplasty                                                                                                                                                                                                                                                                                                      Military insurance beneficiaries, Australian Government Department of Veterans Affairs   9525                80                          January 1, 2001, to December 31, 2012    5138 (53.9)     492 (5.2)                                     38 (0.7)         Chronic opioid use defined as \>90 d of continuous opioid use or \>120-d cumulative use                                                                                                          1 y         9
  Hadlandsmyth et al,^[@zoi200316r69]^ 2018   US          Total knee arthroplasty                                                                                                                                                                                                                                                                                                     Military insurance beneficiaries, Veterans Affairs                                       6653                66                          2013-2015                                5322 (80.0)     866 (13.0)                                    107 (2.0)        Chronic opioid use defined as continuous opioid fills assessed 3, 6, and 12 mo after surgery                                                                                                     1 y         8

Abbreviations: *ICD*, *International Classification of Diseases*; NOW, Newcastle-Ottawa Scale; NR, not reported.

Primary Outcomes {#H2-8-ZOI200316}
----------------

Across the 33 eligible studies based on random-effects analysis, the pooled rate of prolonged opioid use after surgery was 6.7% (95% CI, 4.5%-9.8%) ([Figure 2](#zoi200316f2){ref-type="fig"}), with substantial between-study heterogeneity (*P* \< .001; *I^2^* = 99.96%).

![Forest Plot of Studies Assessing Prolonged Opioid Use After Surgery\
Squares indicate event rates, with horizontal lines representing 95% CIs. The diamond represents the pooled total, with the points of the diamond representing 95% CIs. The data show substantial between-study heterogeneity (*P* \< .001; *I^2^* = 99.96%).](jamanetwopen-3-e207367-g002){#zoi200316f2}

With the exception of anxiety, we were unable to find comparable risk factors across the 2 studies^[@zoi200316r50],[@zoi200316r55]^ that used hazard ratios. Therefore, our analyses on risk factors for prolonged opioid use were derived from studies reporting risk ratios or ORs.

Significantly increased risks were observed among females compared with males (OR, 1.16; 95% CI, 1.08-1.25) and among individuals with a high school degree vs a college degree or higher (OR, 1.20; 95% CI, 1.04-1.37) ([Table 2](#zoi200316t2){ref-type="table"}).

###### Baseline Characteristics Associated With Prolonged Opioid Use After Surgery

  Characteristic                                              Studies, No.   References                                               Random-effects pooled OR (95% CI)   *I*^2^, %   *P* value
  ----------------------------------------------------------- -------------- -------------------------------------------------------- ----------------------------------- ----------- -----------
  **Demographic characteristic**                                                                                                                                                      
  Age                                                                                                                                                                                 
  ≥50 y                                                       NA             NA                                                       1 \[Reference\]                     NA          NA
  \<50 y                                                      2              49, 56                                                   1.83 (0.98-3.48)                    98.71       \<.001
  Body mass index[^a^](#zoi200316t2n1){ref-type="table-fn"}                                                                                                                           
  \<25                                                        NA             NA                                                       1 \[Reference\]                     NA          NA
  25-29.9                                                     4              62-64, 69                                                1.04 (0.52-2.10)                    41.63       .16
  30-34.9                                                     3              62-64                                                    1.21 (0.61-2.38)                    38.58       .20
  35-39.9                                                     3              62-64                                                    0.63 (0.31-1.30)                    0           .54
  ≥40                                                         3              62-64                                                    0.98 (0.42-2.33)                    17.52       .26
  Sex                                                                                                                                                                                 
  Male                                                        NA             NA                                                       1 \[Reference\]                     NA          NA
  Female                                                      14             12, 31, 33, 46, 48, 49, 54, 57, 58, 61, 62, 65, 67, 69   1.16 (1.08-1.25)                    88.87       \<.001
  Race/ethnicity                                                                                                                                                                      
  White                                                       NA             NA                                                       1 \[Reference\]                     NA          NA
  African American                                            7              12, 27, 32, 33, 47, 61, 69                               1.02 (0.92-1.13)                    69.35       .01
  Asian                                                       4              12, 33, 47, 61                                           0.68 (0.45-1.03)                    91.25       \<.001
  Hispanic                                                    5              12, 27, 33, 47, 61                                       0.92 (0.80-1.05)                    79.85       \<.001
  Educational level                                                                                                                                                                   
  College degree or more                                      NA             NA                                                       1 \[Reference\]                     NA          NA
  Less than high school                                       2              12, 30                                                   1.06 (0.56-2.00)                    0           .91
  High school                                                 2              12, 30                                                   1.20 (1.04-1.37)                    0           .63
  Some college                                                2              12, 30                                                   1.10 (0.92-1.33)                    49.41       .16
  Preoperative medication use                                                                                                                                                         
  Antidepressants                                             6              11, 16, 27, 29, 46, 69                                   1.42 (1.11-1.81)                    90.97       \<.001
  Antipsychotics                                              2              11, 16                                                   1.15 (0.90-1.48)                    0           .74
  Benzodiazepines                                             5              11, 16, 29, 46, 69                                       1.53 (1.20-1.95)                    91.72       \<.001
  Opioids                                                     14             12, 27, 29, 32, 33, 51, 52, 56, 58-61, 66, 69            5.32 (2.94-9.64)                    99.57       \<.001
  Substance use                                                                                                                                                                       
  Alcohol                                                     8              11, 12, 29, 31, 47, 49, 53, 60                           1.55 (1.07-2.25)                    90.74       \<.001
  Cocaine                                                     2              16, 29                                                   4.34 (1.50-12.58)                   0           .64
  Marijuana                                                   2              16, 29                                                   0.89 (0.29-2.74)                    0           .36
  Tobacco                                                     10             12, 16, 27, 29-31, 47-49, 60                             1.55 (1.23-1.96)                    95.16       \<.001
  **Medical comorbidities**                                                                                                                                                           
  Mental health conditions                                                                                                                                                            
  Anxiety                                                     9              12, 27, 30, 33, 53, 61-64                                1.14 (1.06-1.23)                    61.10       \<.001
  Bipolar disorders                                           2              33, 61                                                   0.88 (0.79-0.98)                    0           \>.99
  Depression                                                  15             11, 32, 33, 47-49, 52, 53, 56, 61-64, 68, 71             1.54 (1.25-1.91)                    97.90       \<.001
  Mood disorders                                              3              12, 30, 60                                               1.85 (1.11-3.07)                    92.44       \<.001
  Psychiatric disorders                                       5              11, 30, 51, 61, 68                                       1.04 (0.95-1.13)                    0           .75
  Posttraumatic stress disorder                               2              33, 61                                                   1.39 (1.21-1.59)                    0           .37
  Unspecified mental disorders                                5              12, 30, 31, 33, 54                                       1.45 (0.78-2.68)                    53.40       .07
  Pain conditions                                                                                                                                                                     
  Arthritis                                                   4              12, 30, 33, 61                                           1.19 (0.93-1.52)                    94          \<.001
  Back pain                                                   11             12, 16, 29, 33, 49, 51, 56, 61, 65, 67, 68               2.05 (1.63-2.58)                    98.65       \<.001
  Chronic pain                                                5              27, 53, 60, 61, 69                                       1.35 (1.04-1.75)                    85.92       \<.001
  Fibromyalgia                                                7              16, 29, 33, 49, 51, 56, 61                               1.43 (1.15-1.79)                    97.41       \<.001
  Migraine                                                    4              16, 29, 61, 68                                           1.36 (1.02-1.80)                    80.87       .01
  Neck pain                                                   4              12, 30, 33, 61                                           1.12 (1.02-1.23)                    60.17       .06
  Osteoarthritis                                              3              33, 54, 61                                               1.03 (0.96-1.09)                    0           .47
  Unspecified pain disorders                                  9              12, 30-33, 54, 58, 61, 65                                1.45 (1.21-1.72)                    63.24       \<.001
  Other medical conditions                                                                                                                                                            
  Anemia                                                      2              33, 61                                                   1.06 (1.01-1.12)                    0           .88
  Coagulopathy                                                2              33, 61                                                   1.20 (1.08-1.34)                    0           .74
  Cerebrovascular disease                                     2              46, 47                                                   0.90 (0.55-1.46)                    34.07       .22
  Diabetes                                                    5              46, 54, 60, 61, 68                                       1.09 (0.90-1.31)                    59.42       .04
  Hypothyroidism                                              2              33, 61                                                   0.99 (0.95-1.04)                    0           .87
  Liver disease                                               4              33, 47, 61, 68                                           1.23 (0.98-1.54)                    87.56       .005
  Obesity                                                     2              48, 65                                                   1.25 (0.67-2.35)                    87.56       .005
  Pulmonary disease                                           4              48, 65                                                   1.32 (1.07-1.63)                    92.55       \<.001
  Renal disease                                               3              33, 46, 61                                               1.02 (0.97-1.08)                    0           .40
  Substance abuse                                             11             11, 16, 27, 29, 31, 33, 49, 53, 56, 61, 69               1.58 (1.14-2.21)                    98.47       \<.001

Abbreviations: NA, not applicable; OR, odds ratio.

Calculated as weight in kilograms divided by height in meters squared.

Increased risk of prolonged opioid use was associated with use of antidepressants, opioids, benzodiazepines, alcohol, cocaine, or tobacco before surgery ([Table 2](#zoi200316t2){ref-type="table"}). Preoperative use of opioids (OR, 5.32; 95% CI, 2.94-9.64), tobacco (OR, 1.55; 95% CI, 1.23-1.96), or cocaine (OR, 4.34; 95% CI, 1.50-12.58) were identified as having the strongest associations with prolonged use of opioids after surgery.

Medical comorbidities were differentiated into 3 specific categories: psychological, pain-associated conditions, and a broader category composed of disorders such as diabetes, pulmonary disease, and obesity ([Table 2](#zoi200316t2){ref-type="table"}). When evaluating the association between psychological disorders before surgery and prolonged opioid use after surgery, increased risks were observed among participants with diagnoses of anxiety (OR, 1.14; 95% CI, 1.06-1.23), depression (OR, 1.54; 95% CI, 1.25-1.91), and mood disorders (OR, 1.85; 95% CI, 1.11-3.07). In contrast, patients with a diagnosis of bipolar disorder before surgery had significantly lower risks for prolonged opioid use after surgery (OR, 0.88; 95% CI, 0.79-0.98). Among pain conditions aggregated across all studies, prolonged opioid use after surgery was most strongly associated with a history of back pain (OR, 2.05; 95% CI, 1.63-2.58) and fibromyalgia (OR, 1.43; 95% CI, 1.15-1.79) ([Table 2](#zoi200316t2){ref-type="table"}).

Sensitivity and Additional Analyses {#H2-9-ZOI200316}
-----------------------------------

Our primary findings remained largely unchanged in leave-one-out analyses (eTable 4 in the [Supplement](#note-ZOI200316-1-s){ref-type="supplementary-material"}). No evidence of publication bias was found with the Egger regression-based test (intercept, --20.99; 95% CI, --46.04% to 4.07%; SE, 12.28; *P* = .10) (eFigure in the [Supplement](#note-ZOI200316-1-s){ref-type="supplementary-material"}). Studies involving only opioid-naive participants before surgery had lower pooled rates of prolonged opioid use after surgery (1.2%; 95% CI, 0.4%-3.9%). In the restricted analysis assessing chronic opioid use,^[@zoi200316r11],[@zoi200316r50],[@zoi200316r57],[@zoi200316r67],[@zoi200316r68],[@zoi200316r69],[@zoi200316r71]^ we observed a pooled rate of 2.3% (95% CI, 0.5%-10.6%). Similarly, in the 10 studies^[@zoi200316r12],[@zoi200316r30],[@zoi200316r31],[@zoi200316r33],[@zoi200316r46],[@zoi200316r53],[@zoi200316r55],[@zoi200316r58],[@zoi200316r59],[@zoi200316r61]^ defining prolonged opioid use as the filling of at least 1 opioid prescription within the first 90 days after surgery and the filling of at least 1 additional opioid prescription from 91 to 180 days after surgery, the pooled rate was 13.8% (95% CI, 7.9%-23.0%). No significant difference was observed in a comparison of major vs minor surgical procedures (pooled rate, 7.0%; 95% CI, 4.9%-9.9% vs 11.1%; 95% CI, 6.0%-19.4%; (*P* = .20). Results from meta-analyses of other study-level factors are presented in [Table 3](#zoi200316t3){ref-type="table"}.

###### Random-Effects Pooled Rates From Additional Analyses

  Characteristic                                                                                         Studies, No.   Participants, No.   References                                                Pooled rate (95% CI)   *P* value   *I*^2^, %   *P* value
  ------------------------------------------------------------------------------------------------------ -------------- ------------------- --------------------------------------------------------- ---------------------- ----------- ----------- -----------
  Country of patient enrollment                                                                                                                                                                                                                      
  US                                                                                                     26             1 854 006           12, 16, 27, 29-33, 47-52, 55-58, 60-64, 66, 69            5.8 (3.7-9.0)          .09         99.97       \<.001
  Non-US                                                                                                 7              68 737              46, 53, 54, 59, 65, 67, 68                                10.7 (6.2-18.1)        99.56       \<.001      
  Length of follow-up, mo                                                                                                                                                                                                                            
  \>6                                                                                                    22             1 715 595           11, 16, 27, 29, 33, 47-50, 52, 54, 56, 57, 60-65, 67-69   5.4 (3.1-9.5)          .12         99.97       \<.001
  ≤6                                                                                                     11             207 148             12, 30-32, 46, 51, 53, 55, 58, 59, 66                     9.6 (6.2-14.6)         99.86       \<.001      
  Source population or study setting                                                                                                                                                                                                                 
  Commercial insurance beneficiaries                                                                     14             1 124 786           11, 12, 16, 27, 29-32, 48, 49, 51, 52, 56, 57             6.0 (3.5-1.2)          NA          99.97       \<.001
  Hospital institution data                                                                              12             713 818             33, 47, 53, 55, 58, 59, 61-65, 72                         9.8 (2.5-31.5)         99.95       \<.001      
  Military insurance beneficiaries                                                                       5              41 334              50, 66-69                                                 5.4 (2.9-9.8)          99.36       \<.001      
  National insurance plans                                                                               2              42 805              46, 54                                                    3.9 (2.5-6.2)          97.18       \<.001      
  Major vs minor surgery                                                                                                                                                                                                                             
  Major surgery                                                                                          27             1 228 350           16, 27, 29, 31-33, 46-51, 53, 55-65, 67-69                7.0 (4.9-9.9)          .20         99.94       \<.001
  Minor surgery                                                                                          4              16 275              30, 52, 54, 66                                            11.1 (6.0-19.4)        98.75       \<.001      
  Orthopedic vs nonorthopedic surgery                                                                                                                                                                                                                
  Orthopedic                                                                                             23             399 248             29, 31, 33, 48-54, 56-60, 62-69                           12.1 (9.7-14.9)        .07         99.84       \<.001
  Nonorthopedic                                                                                          6              806 128             16, 27, 30, 32, 47, 61                                    1.7 (0.2-13.7)         NA          99.97       \<.001
  Other study-level analyses                                                                                                                                                                                                                         
  Only opioid-naive patients before surgery                                                              8              902 689             11, 12, 30-32, 46, 50                                     1.2 (0.4-3.9)          NA          99.97       \<.001
  Similar definitions for chronic opioid use after surgery[^a^](#zoi200316t3n1){ref-type="table-fn"}     7              760 723             11, 27, 50, 57, 67-69                                     2.3 (0.5-1.6)          NA          99.98       \<.001
  Similar definitions for prolonged opioid use after surgery[^b^](#zoi200316t3n2){ref-type="table-fn"}   10             175 486             12, 30, 31, 33, 46, 53, 55, 58, 59, 61                    13.8 (7.9-23.0)        NA          99.93       \<.001

Abbreviation: NA, not applicable.

Included studies defining opioid use after surgery as the receipt of opioids for 10 opioid fills or more, 90 or more consecutive days' supply of opioids, or 120 cumulative days in the first year after surgery after excluding the first 90 postoperative days.

Included studies defining prolonged opioid use as 1 opioid fill or more within 91 to 180 days after surgery.

Discussion {#H1-4-ZOI200316}
==========

This systematic review and meta-analysis of observational studies^[@zoi200316r11],[@zoi200316r12],[@zoi200316r16],[@zoi200316r27],[@zoi200316r29],[@zoi200316r30],[@zoi200316r31],[@zoi200316r32],[@zoi200316r33],[@zoi200316r46],[@zoi200316r47],[@zoi200316r48],[@zoi200316r49],[@zoi200316r50],[@zoi200316r51],[@zoi200316r52],[@zoi200316r53],[@zoi200316r54],[@zoi200316r55],[@zoi200316r56],[@zoi200316r57],[@zoi200316r58],[@zoi200316r59],[@zoi200316r60],[@zoi200316r61],[@zoi200316r62],[@zoi200316r63],[@zoi200316r64],[@zoi200316r65],[@zoi200316r66],[@zoi200316r67],[@zoi200316r68],[@zoi200316r69]^ extend the results of a previous meta-analysis^[@zoi200316r73]^ reporting prolonged opioid use among approximately 1 in 10 individuals undergoing a major or minor surgical procedure. Our analyses indicated that approximately 7% of patients filled opioid prescriptions at 3 months and more than 1 year after surgery, a time beyond the normal postoperative recovery period.^[@zoi200316r74]^ A higher rate was observed when prolonged opioid use was defined as the filling of at least 1 prescription for opioids within 91 to 180 days after surgery. However, our primary pooled rate was attenuated when we restricted our analyses to patients considered as opioid naive before surgery or to studies involving a more conservative definition of prolonged use that is commonly used in the medical literature to characterize chronic opioid use. Although these rates may appear to be relatively low, the negative consequences that prolonged opioid use may impose on public health is perhaps better elucidated when indexed to the number of surgical procedures performed annually in the US. In 2010, approximately 51.4 million inpatient and 48.3 million ambulatory surgical procedures were estimated to have been performed in the US.^[@zoi200316r75],[@zoi200316r76]^ Based on previous studies^[@zoi200316r77]^ reporting that 4 of 5 patients undergoing surgery receive opioids, our pooled rate of 6.9%, when extrapolated to the total number of surgical procedures, implies that up to 5.7 million Americans may potentially become persistent opioid users annually after surgery. Of note, individuals with prolonged opioid use after surgery constitute a group with potentially significant risk of chronic use. Therefore, prioritizing strategies that mitigate the transition of patients undergoing surgery to persistent opioid use while still optimizing the management of postoperative pain is of importance.

A possible approach to reducing the burden of prolonged opioid use is to characterize the underlying mechanisms, including patient-level risk factors, that may be associated with prolonged and/or chronic use of opioids after surgery. This approach, in part, rests on the assumption that patient-level risk factors associated with prolonged opioid use may be modifiable and can be used in screening for at-risk individuals.^[@zoi200316r74]^ Our results indicate that preoperative exposure to medications, such as opioids, antidepressants, benzodiazepines, or cocaine; demographic factors, such as sex; and presence of medical comorbidities, including chronic pain, back pain, substance abuse, mood disorders, or depression before surgery, had some of the strongest associations with prolonged opioid use after surgery. Congruent with previous reviews,^[@zoi200316r73],[@zoi200316r78]^ the strongest association in the current study was observed with preoperative opioid use, wherein individuals who had filled at least 1 opioid prescription in the year before surgery had a 5.3-fold risk of prolonged opioid use after surgery (pooled OR, 5.32; 95% CI, 2.94-9.64). These findings of increased risk of preoperative opioid use and prolonged use after surgery was further corroborated when we restricted our analyses to studies enrolling opioid-naive participants at baseline; the pooled rate of prolonged opioid use after surgery decreased more than 5-fold. Appropriate prescribing of the dose and quantity of opioids after surgery, the evaluation of opioid use in patients before surgery, and attempts to modify patient-level risk factors when possible or to treat underlying medical conditions before surgery may be included as part of a comprehensive strategy to reduce prolonged opioid use after surgery. Multimodal analgesia, psychobehavioral management of pain, and regional and neuraxial anesthesia have also been listed in the literature^[@zoi200316r78],[@zoi200316r79],[@zoi200316r80]^ as strategies associated with reducing the transition to prolonged opioid use after surgery.

Although our analyses suggest that surgery may be associated with long-term opioid use, it is possible that the observed association was enhanced by confounding from an underlying chronic pain condition, the developing of persistent postsurgical pain, or surgical procedures exacerbating preexisting conditions and thus warranting long-term opioid management. Persistent postsurgical pain is a recognized complication of surgery and has been reported after common surgical procedures, including cesarean delivery or hip replacement.^[@zoi200316r38],[@zoi200316r81]^ Several studies^[@zoi200316r38],[@zoi200316r81],[@zoi200316r82],[@zoi200316r83],[@zoi200316r84]^ suggest that between 20% and 60% of individuals who undergo surgical procedures may transition from acute to persistent or chronic postsurgical pain. Because opioids were considered the standard of care for chronic noncancer pain management for studies included in this meta-analysis,^[@zoi200316r2],[@zoi200316r10]^ the findings suggest that a high rate of prolonged opioid use after surgery may reflect the expected opioid use patterns among individuals with persistent postsurgical pain or underlying chronic pain. Because of a lack of information in the included studies, we were unable to assess the association between these confounding factors and opioid use after surgery in our analyses.

Of note, other mechanisms not associated with surgical pain before or after undergoing the procedure could have explained the findings of increased prolonged opioid use with surgery. Because major surgical procedures are likely to be associated with higher frequencies or intensities of postoperative pain and perhaps with a longer recovery time compared with minor surgical procedures, we expected significant differences in the pooled rate of prolonged opioid use in major vs minor surgical procedures. However, we found no such evidence in our subgroup analysis. Although a similar finding was recently reported in a large retrospective study of US adults undergoing minor or major surgical procedures,^[@zoi200316r12]^ a meta-analysis by Mohamadi et al^[@zoi200316r72]^ reported significant differences in prolonged opioid use between these categories of procedures. Therefore, further research should aim to delineate the causal mechanisms of continuous use of opioids in the postoperative period, particularly in the context of surgical pain.

Limitations {#H2-10-ZOI200316}
-----------

This study has limitations. Because the studies included in our analyses were observational by design, our findings may be prone to several forms of systematic bias, including selection bias and measurement errors. Of importance, our findings may have been subject to confounding by the underlying indication and inadequate bias adjustment. Second, although we performed several sensitivity analyses to explore the sources of heterogeneity, we were unable to explain the substantial heterogeneity present in most of our analyses. We used a random-effects model for our analyses, with the a priori assumption that the included studies would be heterogenous in their design, sample size, definitions of prolonged opioid use and risk factors, and adjustment of covariates. Third, because of a paucity of eligible studies and suboptimal reporting, we were unable to exclude studies involving participants with chronic opioid use at baseline, participants with preexisting pain disorders, or participants with a diagnosis of cancer before surgery---conditions that are frequently managed with opioids. Of note, the inclusion of these individuals may have led to an overestimation in the magnitude of prolonged opioid use after surgery.^[@zoi200316r85]^ In addition, although less likely to be substantial, it is unknown the extent to which some of the eligibility criteria (eg, requiring studies to have reported the rate and risk factors for prolonged use) or not contacting authors may have affected the magnitude of observed association.

Despite these limitations, confidence in our findings is perhaps reinforced because of the absence of small-study bias and consistent results from study-level factors that might have moderated our observed association. Nevertheless, further research is needed to quantify the effect of these various sources of bias on our study findings.

Conclusions {#H1-5-ZOI200316}
===========

In this study, preoperative use of opioids and cocaine and the presence of comorbid pain conditions before surgery had the strongest associations with prolonged opioid use after surgery. These largely modifiable patient-level risk factors may be included as part of a comprehensive strategy to screen for at-risk individuals requiring transition to nonopioid interventions after surgery while ensuring appropriate short-term opioid use to manage postoperative pain. Research is needed to further investigate the association between surgical pain and prolonged opioid use after surgery.
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